
You are currently analyzing a forecasting question to generate an outside view prediction.

The forecasting question is:
Will PFE's market close price on 2026-03-13 be higher than its market close price on 2026-03-02?

Question background:
Pfizer Inc. is a company that is listed on the S&P 500 index. It's ticker is PFE. It's last close price as of the creation of this question (2026-03-01 16:40:53) is 27.65. You can find more information about Pfizer Inc. at https://finance.yahoo.com/quote/PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

`{"format":"close_price_rises","info":{"ticker":"PFE"}}`

This question's outcome will be determined by the specific criteria below. These criteria have not yet been satisfied:
This question will resolve based on the latest market close price of PFE. If it is higher than the close price on 2026-03-02, the question will resolve to 'Yes'. The close price will be pulled from the Yahoo Finance API.

Additional fine-print:
Stock splits and reverse splits will be accounted for in resolving this question. Forecasts on questions about companies that have been delisted (through mergers or bankruptcy) will resolve to their final close price.

Question metadata:
- Opened for forecasting: 2026-03-02T08:24:21Z
- Resolves: 2026-03-13T01:26:47Z
- Note: Unless the question title specifies otherwise, the Forecast Opening Date of 2026-03-02T08:24:21Z should be considered the start of the question's resolution window. Events before this date do not count toward resolution.

IMPORTANT: Today's date is 2026-03-02. All dates before today's date are in the PAST. All dates after today's date are in the FUTURE. Use today's date to correctly evaluate whether sources describe past events or future predictions. Any information source which refers to events before today's date of 2026-03-02 should not be considered as speculative but rather an historical document.

Historical context:
=== STOCK RETURN DISTRIBUTION (Programmatic Analysis) ===
Ticker: PFE | Window: 2026-03-02 to 2026-03-13 (9 trading days)
Latest close price: $27.65
Reference close price (2026-03-02): $27.65
Return so far: +0.00% (down from reference)

HISTORICAL BASE RATE (9-trading-day returns, N=2506 overlapping windows):
  P(positive 9-day return): 52.4%
  Mean return: +0.24%
  Median return: +0.25%
  Std dev: 4.41%
  Percentiles: 5th=-6.89%, 25th=-2.34%, 75th=+2.74%, 95th=+7.34%

RECENT CONTEXT:
  5-day trailing return: +3.75% (89th percentile historically)
  1-month trailing return: +6.92% (85th percentile historically)
  3-month trailing return: +9.30% (80th percentile historically)
  30-day realized volatility: 24.3% (annualized)

CONDITIONAL BASE RATES (same historical data, overlapping windows, filtered by current conditions):
  Unconditional:                           P(up) = 52.4% (N=2506)
  3-month return > 20%:                    P(up) = 17.1% (N=82, Δ=-35.4pp)
  Price in top decile of 52wk range:       P(up) = 58.3% (N=254, Δ=+5.8pp) <- CURRENTLY APPLICABLE
  Price in bottom decile of 52wk range:    P(up) = 48.1% (N=266, Δ=-4.3pp)
  Prior 5-day return > 0:                  P(up) = 53.8% (N=1296, Δ=+1.3pp) <- CURRENTLY APPLICABLE
  Prior 5-day return < 0:                  P(up) = 50.9% (N=1195, Δ=-1.6pp)
  30-day vol above median:                 P(up) = 47.9% (N=1238, Δ=-4.5pp) <- CURRENTLY APPLICABLE
  30-day vol below median:                 P(up) = 56.4% (N=1238, Δ=+3.9pp)

This is a PROGRAMMATIC computation from actual historical price data. Use the historical base rate as an anchor and adjust for current conditions.
=== END STOCK RETURN DISTRIBUTION ===

<QuestionSource url="https://finance.yahoo.com/quote/PFE">
## Summary of Yahoo Finance Article on PFE (Pfizer Inc.)

**Disclaimer:** The article content appears to be a partially extracted Yahoo Finance stock page, with some formatting artifacts and incomplete sections. Some data points may reflect a snapshot from around late February/early March 2026.

---

### Key Price & Trading Data
- **Previous Close:** $27.10
- **Open:** $27.16
- **Day's Range:** $27.09 – $27.67
- **52-Week Range:** $20.92 – $27.94
- **Volume:** 29,724,256 (vs. Avg. Volume of 47,872,928)
- **1-Year Price Target (Analyst Consensus):** $28.43

### Valuation & Financials
- **Market Cap:** $157.21B
- **Forward P/E:** 9.33 (vs. Trailing P/E of 20.33)
- **Revenue (TTM):** $62.58B
- **Net Income (TTM):** $7.75B
- **Diluted EPS (TTM):** $1.36
- **Forward Dividend & Yield:** $1.72 (6.22%)
- **Total Cash:** $14.99B

### Notable News & Analyst Commentary
- Pfizer announced **Phase 3 trial progress for PADCEV** and received **full FDA approval for BRAFTOVI** in colorectal cancer, representing oncology portfolio advancements.
- Analysts note **concerns about revenue forecasts and pipeline visibility**.
- One analyst report flags an **EPS decline expected in 2026**.
- A Seagen impairment charge and Metsera tolerability data were characterized as **"incrementally negative"** for Pfizer.
- **Earnings Date** is scheduled for **April 28, 2026**.
- Broader market context noted: major indices were down sharply on the referenced day, with the **VIX jumping ~15% to above 20**, driven by AI disruption fears affecting big tech.
</QuestionSource>


<Summary source="https://www.barchart.com/stocks/quotes/PFE/technical-analysis">
**Disclaimer:** The article extracted from Barchart.com does not contain any specific technical analysis data or numerical values for PFE (Pfizer). The content retrieved is purely definitional/educational, explaining the methodology behind various technical indicators rather than providing actual readings for the stock. No actionable data points were extracted.

---

## Summary: Barchart.com PFE Technical Analysis Page – Methodology Overview

The page is intended to display results of **16 common technical indicators** for PFE across different time periods, but the extracted content only contains explanations of those indicators rather than actual values. The indicators described include:

- **Moving Averages** – Used to smooth price trends; crossovers signal bullish/bearish shifts
- **Stochastic Indicators (Raw, %K, %D)** – Measure where price closed relative to its range over a given period (0–100% scale)
- **Relative Strength Index (RSI)** – Overbought/oversold indicator on a 0–100 scale
- **Average True Range (ATR) & Daily Range metrics** – Volatility measures; high values often signal market bottoms or potential reversals
- **Average Directional Index (ADX), +DI, -DI** – Trend strength indicators; below 20 = no trend, above 25 = trending market
- **Historic Volatility** – Annualized standard deviation of price returns

**No specific PFE indicator values, signals, or trend conclusions were available in the extracted content.**
</Summary>

<Summary source="https://www.morningstar.com/stocks/xwbo/pfe/quote">
## Summary: Morningstar Profile of Pfizer Inc. (PFE) — February 27, 2026

**Disclaimer:** Some content in this article appears to be partially obfuscated or encoded (particularly competitor ratings and stock style data), which may limit the completeness of this summary.

### Trading Information (as of article date)
- **Previous Close Price:** €23.31
- **Day Range:** €23.12–€23.16
- **52-Week Range:** €18.70–€25.50
- **Shares Outstanding:** 5.69 billion
- **Market Cap:** €131.43 billion

### Key Valuation Metrics
- **P/E (Normalized):** 8.14 (vs. GSK at 16.00, LLY at 40.57)
- **Price/Sales:** 2.40
- **Dividend Yield (Trailing):** 6.32%
- **Dividend Yield (Forward):** 6.25%

### Financial Strength
- **Current Ratio:** 1.16
- **Quick Ratio:** 0.80
- **Interest Coverage:** 3.59 (notably lower than GSK's 11.52)

### Profitability
- **Return on Equity (Normalized):** 20.61%
- **Return on Invested Capital (Normalized):** 13.07%

### Recent News Headlines Noted
- Positive results from a combined Merck/Pfizer bladder-cancer trial
- Pfizer acquired exclusive rights to an obesity drug in China
- FDA granted Priority Review for expanded Hympavzi approval
- Pfizer's stock fell following mixed response to weight-loss drug data
- Pfizer sales declined due to lower COVID-19 drug demand
- Novavax struck a license deal with Pfizer for Matrix-M Adjuvant

### Company Overview
- One of the world's largest pharmaceutical firms with ~$60 billion in annual sales
- Prescription drugs and vaccines represent the majority of revenue
- International sales account for ~40% of total, with emerging markets as a significant contributor
- Approximately 81,000 employees
</Summary>

<Summary source="https://charts.equityclock.com/pfizer-inc-nysepfe-seasonal-chart">
**Disclaimer:** The article is primarily a seasonal analysis chart page with limited textual content. Much of the data (e.g., the actual charts) may not have been fully captured in the extraction.

---

## Summary: Pfizer (PFE) Seasonal Chart – Equity Clock

The article presents a seasonal analysis of Pfizer Inc. (NYSE: PFE) stock performance based on historical patterns over the past 20 years.

### Key Findings:

- **Optimal Seasonal Window:** A **Buy Date of July 9** and a **Sell Date of October 3** has historically been identified as the strongest seasonal trading window for PFE.
- **Average Return:** This window has produced a **geometric average return of 2.16% above the S&P 500 Total Return Index benchmark** over the past 20 years.
- **Success Rate:** The seasonal trade showed **positive results vs. the benchmark in 14 out of 20 periods**, indicating a reasonably strong historical hit rate.
- **Long-term Outperformance:** The strategy outperforms the relative buy-and-hold performance of PFE by an average of **7.62% per year**.
- **Sector Correlation:** The identified seasonal window for PFE **correlates poorly** with the broader Healthcare sector's period of seasonal strength (April 25 – December 4).

The article does not contain information directly relevant to the March 2026 timeframe in question.
</Summary>


<Summary source="https://intellectia.ai/stock/PFE/forecast">
**Disclaimer:** This article is from Intellectia.ai, an algorithmic/AI-based stock analysis platform. The predictions are model-generated and should be treated as less reliable than established financial institutions or named analyst sources.

---

## Summary: PFE Price Prediction Article (Intellectia.ai)

### Recent Price Performance
- PFE stock fell **-10.76%** in 2024, decreased **-6.43%** in 2025, but has gone **up 9.81%** in 2026 (as of the article's data).

### Technical Signals (as of March 2, 2026)
- **Bullish signals (5):** AO_5_34 > 0, MOM_10 > 0, MACD_12_26_9 > 0, Price crosses above 10-day SMA, 5-day SMA crosses above 10-day SMA.
- **Bearish signals (1):** Williams %R (14 days) > -20.
- **Overall technical rating:** "Strong Buy"
- Moving average trend as of March 2, 2026: **0 negative signals, 4 positive signals** (bullish lean).

### Seasonal Patterns (model-based)
- **November** historically shows the highest probability of positive returns (**80%**).
- **January** shows the lowest probability (**18.18%**).

### Price Forecasts (model-generated)
- **December 2026:** Average price target of **$26.34**, ranging between **$25.60 (low)** and **$32.01 (high)**.
- **December 2030:** Average price target of **$42.89**, ranging between **$40.06 (low)** and **$51.21 (high)**.
</Summary>

<Summary source="https://capitalizator.com/seasonality/PFE">
**Disclaimer:** The extracted content from this article is largely incomplete — it appears to be a tool/platform description rather than a full data-rich article. No specific seasonal data, charts, or numerical statistics for PFE were successfully extracted.

---

## Summary: Capitalizator – PFE Seasonality Analysis

The article is from **Capitalizator**, a platform that provides **seasonality analysis** for various financial assets, including stocks, ETFs, forex, crypto, and commodities.

### Key Concepts Described:

- **Seasonality analysis** identifies **recurring patterns in asset prices** over a calendar year by analyzing historical averages across multiple timeframes: **5, 10, 20 years, and all-time**.
- The analysis displays **percentage change from the start of the year**, visualized in a chart format.
- The platform supports standard ticker inputs (e.g., PFE for Pfizer).

### Timeframe Interpretation Framework:
| Timeframe | Purpose |
|-----------|---------|
| 5 Years | Captures recent market regimes |
| 10 Years | Standard baseline |
| 20 Years | Filters out economic cycles |
| All-Time | Long-term structural trends |

- The platform emphasizes that a **true seasonal pattern** should be **consistent across multiple timeframes** — a trend appearing only in the 5-year average may be a short-term anomaly, while alignment across all periods suggests **structural seasonality**.

**No specific PFE seasonal data or statistics were available in the extracted content.**
</Summary>

<Summary source="https://www.barchart.com/stocks/quotes/PFE/seasonality-chart">
**Disclaimer:** The article does not provide the actual numerical seasonal data/matrix for PFE (Pfizer) stock — only the methodology and explanatory text for how Barchart.com calculates and presents seasonal returns. No specific monthly return figures, percentage-positive values, or historical performance statistics for PFE are visible in the extracted content.

---

## Summary: PFE Seasonal Returns Methodology (Barchart.com)

This Barchart.com page presents **seasonal return data for Pfizer (PFE) stock**, with historical data going back to **2010 where available**. The page is structured around a **seasonal matrix** and a **summary table**, explained as follows:

### Key Methodological Points:
- **Seasonal average monthly return** is calculated by averaging each calendar month's return across all available years.
- **For stocks like PFE**, returns are calculated on a **total return (dividend-adjusted)** basis.
- The **Summary table** provides, for each month:
  - **% Positive / % Negative** months historically
  - **Median, Best, and Worst** returns
  - **Absolute Average, Absolute Best, and Absolute Worst** returns (always non-negative, useful for directional and neutral traders)

### Important Caveat Highlighted by Barchart:
> Seasonal patterns reflect **past data only** and **may not predict future performance**. Relying solely on seasonality can lead to missed opportunities or increased risks.

No specific PFE monthly figures were retrievable from the extracted content.
</Summary>


<Summary source="https://www.deloitte.com/us/en/insights/industry/health-care/key-factors-for-successful-drug-launch.html">
## Summary of Article: Pharmaceutical Drug Launch Performance Analysis (Deloitte)

**Source:** Deloitte Center for Health Solutions analysis of 284 new drugs launched in the U.S. between 2012–2021.

**Disclaimer:** This article is about general pharmaceutical industry launch performance and does not contain any specific information about Pfizer's stock price, recent financial performance, or near-term market outlook. Its relevance to the forecasting question is limited.

---

### Key Facts & Statistics:
- **One-third of drug launches miss analyst expectations**, based on analysis of 284 new drugs (new indications for small molecules and biologics) launched in the U.S. between 2012–2021
- Average **first-year launch revenue** varies significantly by company size:
  - Large companies (>$25B revenue): **$142 million**
  - Midsize companies ($1B–$25B revenue): **$283 million**
  - Small companies (<$1B revenue): **$40 million**
- **Midsize companies** have consistently outperformed the industry average in meeting/exceeding analyst forecasts over 10 years, with less variability
- **Large companies** track the industry average but show the **most variability** in performance over time

### Key Reasons Drugs Miss Expectations:
1. Market access issues (formulary exclusions, pricing, rebates)
2. Poor product differentiation
3. Inadequate understanding of market/customer needs
4. Unfavorable clinical findings
5. Cross-functional coordination failures (especially at large companies)
6. Overreliance on legacy playbooks

### Structural Observations Relevant to Large Pharma (e.g., Pfizer):
- Large companies are **more likely to miss due to poor market understanding and weak product differentiation**, not lack of expertise
- Large companies are **less likely to miss due to market access issues**, given stronger payer relationships
- Recommended solutions include separating specialty/rare disease assets into dedicated business units and improving early commercial-clinical collaboration
</Summary>

<Summary source="https://www.lek.com/insights/hea/us/ei/variability-large-pharma-launch-performance">
## Summary

**Disclaimer:** This article is from L.E.K. Consulting and focuses on pharmaceutical product launch performance analysis. It contains **no information directly relevant to PFE's stock price movements** between March 2 and March 13, 2026.

---

### Key Findings from L.E.K. Consulting's Pharma Launch Analysis

**Scope:** Examined 62 product launches from the top 10 pharmaceutical companies by market cap between 2015–2019.

**Overall Launch Performance:**
- Average U.S. revenue per product in Year 3 post-approval: ~$600 million
- Highest-performing launch: $6.3 billion; lowest: <$10 million
- Median revenue per product: $260 million
- ~50% of all products launched over the past 15 years underperformed pre-launch consensus forecasts by >20%

**Company-Level Variation:**
- A **ninefold difference** exists between highest- and lowest-performing companies in average Year 3 revenue ($1.9B vs. $0.2B)

**Two Key Drivers of Launch Success:**
1. **Focus on core therapeutic areas** – 80% of launches were in established areas; these generated 2.4x higher average revenues ($670M vs. $280M) compared to non-core launches
2. **Early life cycle expansion** – Top three performers averaged 1.4 indication extensions per product within three years vs. 0.4 for bottom performers

**Notable Caveat:** The Inflation Reduction Act (2022) may compress revenue windows, altering ROI calculations for indication expansions.
</Summary>

<Summary source="https://link.springer.com/article/10.1007/s11293-023-09778-5">
## Article Summary

**Disclaimer:** This article is an academic study focused on historical stock performance during epidemics/pandemics (2000–2020) and does not contain any specific information about PFE's current or future price movements.

---

### Key Findings

**Core Result:** Health care company stocks tend to **outperform the market during pandemics**, but **not during epidemics**, in the short run.

**Influencing Factors:**
- The specific **subindustry** within health care significantly influenced abnormal returns
- The **geographic region** of the stock market also significantly influenced abnormal returns

### Referenced Prior Research
- **Nippani & Washer (2004):** SARS had limited statistically significant negative impact on most stock markets, except Vietnam and China
- **Chen et al. (2007):** SARS caused ~29% stock price decline in Taiwan's tourism sector within one month
- **Ichev & Marinč (2018):** Ebola outbreak most strongly affected companies with West African business exposure; media intensity amplified effects
- **Pandey & Kumari (2021):** COVID-19 significantly and negatively affected global equity markets, with Asian markets most impacted
- **Chowdhury & Abedin (2020):** U.S. markets reacted negatively to confirmed COVID-19 cases and deaths

### Relevance to Forecasting Question
This article provides **no direct information** relevant to PFE's price movement between March 2 and March 13, 2026.
</Summary>


<Summary source="https://icfs.com/financial-knowledge-center/sp-500-weekly-drops-5">
## Article Summary

**Source:** An educational/financial advisory resource (appears to be a financial education or advisor training platform)

**Topic:** Historical S&P 500 behavior following weekly declines of 5% or more (1980–2025)

---

### Key Statistical Findings

- Between 1980 and end of 2025, the S&P 500 dropped **5% or more in a single calendar week approximately 40 times** (~once every 14 months)
- These severe weekly drops occurred in only **1.7% of all calendar weeks**; in 98.3% of weeks, the index held steady, gained, or declined less than 5%
- After a weekly decline of 5%+, the **following week produced a gain approximately 60–65% of the time**

### Clustering Patterns
- Severe weekly drops rarely arrive in isolation — they cluster around crisis events
- **2008 Financial Crisis:** 6 such weeks; **COVID-19:** 4 such weeks in a single month
- Largest single-week declines were associated with **financial system stress**, not merely economic slowdowns

### Notable Historical Episodes Referenced
- **October 2008:** ~18.2% weekly decline, followed by another ~18.2% decline the next week (the only consecutive occurrence in the dataset)
- **March 2020 (COVID):** VIX spiked above 80; full S&P 500 recovery by August 2020; 150%+ four-year return from the March 23 low
- **2022 Bear Market:** Only one week met the 5%+ threshold (week of June 17); damage came in gradual 3–4% weekly increments over 9 months
- **April 2025 ("Liberation Day" tariff crash):** S&P 500 lost ~9% the week of April 4 (worst since March 2020); recovered to pre-crash levels by early May; reached **new all-time high by June 27, 2025** — full round trip took ~3 months

### Forward Return Context
- The **worst four-week forward return** after a 5%+ weekly decline (~−19.5%) followed the October 1987 crash
- Despite worst-case scenarios, **12-month forward returns from those troughs were strongly positive**
- ~78% of the market's best individual trading days have occurred during bear markets or in the first two months of a new bull market

### Caveats Noted by Authors
- The ~40 instances since 1980 are **not a statistically robust sample** for forward-looking probability claims
- The 62% next-week recovery rate is **descriptive, not predictive**
- A future 5%+ weekly decline could defy historical patterns
- Data applies to the **S&P 500 index**, not individual stocks or sectors

---

*Note: This article does not specifically discuss PFE/Pfizer and focuses on broad S&P 500 index behavior. Its relevance to the forecasting question is indirect, pertaining to general market recovery tendencies following sharp declines.*
</Summary>

<Summary source="https://www.nasdaq.com/articles/sp-500-just-went-9-days-row-heres-what-history-says-happens-next">
## Article Summary: "The S&P 500 Just Went Up 9 Days in a Row. Here's What History Says Happens Next."

**Source:** Nasdaq (authored via The Motley Fool)

---

### Key Context & Facts

- The S&P 500 fell sharply from its February all-time high, with the Dow dropping as much as **18.8%** and the S&P 500/Nasdaq briefly entering **bear market territory (>20% decline)** following President Trump's April 2 tariff announcement (10% global tariff + "reciprocal tariffs").
- A historic rally occurred on **April 9** after Trump announced a **90-day pause** on reciprocal tariffs (excluding China).
- From **April 22 through May 2**, the S&P 500 rose for **nine consecutive trading days**, gaining **10.2%** — roughly an average full year's worth of returns.
- This represents the **28th time since 1954** the S&P 500 has rallied for at least nine straight days, and only the **4th time** it gained more than 6% during such a streak.

---

### Named Source Opinion

**Ryan Detrick, CMT (Carson Group):** Analyzed the last 10 instances where the S&P 500 climbed eight straight sessions with a total gain exceeding 6%:
- The S&P 500 posted **positive returns 80% of the time** over the subsequent 1-, 3-, and 6-month periods.
- **7 of 9 available 12-month data points** showed positive results.
- Average **one-year return following such streaks: 13.4%** (median: 15.0%), compared to the S&P 500's historical average of 9.2% (median: 10.4%).
- **3 of the last 4 instances** resulted in gains exceeding 20% over the following year.
- Detrick characterized this as evidence "the lows are indeed in and this isn't a bear market rally."

---

### Cautionary Notes (Article Author)

- The dataset is **small** (few data points), limiting statistical reliability.
- Returns don't differ dramatically from long-term S&P 500 averages.
- **Headwinds cited:** Low consumer sentiment, GDP contraction in Q1, ongoing trade policy uncertainty, and an **expensive S&P 500 valuation** relative to historical averages.
- Earnings forecasts may be revised downward as tariff impacts on businesses and consumers become clearer.

---

### Broader Investment Takeaway

The article references Warren Buffett's advice: ignore short-term fluctuations and focus on businesses with strong long-term profit potential at fair prices, regardless of macroeconomic noise.

---

**Disclaimer:** This article focuses on the **S&P 500 broadly** and does not mention **PFE (Pfizer)** specifically. Its relevance to the forecasting question is limited to general market direction signals.
</Summary>

<Summary source="https://www.fool.com/investing/2026/03/01/sp-500-did-this-for-21st-time-in-100-years-history/">
## Summary: S&P 500 Seven-Month Winning Streak Analysis (The Motley Fool, March 1, 2026)

**Author:** David Dierking

### Key Context
The S&P 500 completed a **seven consecutive positive monthly return streak** from May to November 2025 — the **21st such occurrence in the past ~100 years**. The author analyzed the 20 prior instances to assess what forward 12-month returns typically look like after such streaks.

### Key Statistics: Post-Streak Forward 12-Month Returns (20 historical instances)
| Metric | Value |
|---|---|
| Positive outcomes | 14/20 (70%) |
| Average return | 7.2% |
| Median return | 5.7% |
| Range | -35.7% to +38.1% |

### Comparison: All 12-Month Forward Returns (~1,166 data points, ~100 years)
| Metric | Value |
|---|---|
| Positive outcomes | 69.2% |
| Average return | 8.1% |
| **Median return** | **9.8%** |

### Key Takeaway (from the article)
- The **probability of positive returns** after a seven-month streak (~70%) is nearly **identical** to the base rate for any random 12-month period (~69%).
- However, the **median forward return after a streak (5.7%) is roughly half** the overall historical median (9.8%), suggesting **below-average returns are historically likely** following such streaks.
- The author explicitly notes the **small sample size (20)** as a limitation but concludes that **underperformance relative to long-term averages appears likely** following the completed streak.

*Note: This article focuses on broad S&P 500 index behavior and does not specifically address PFE/Pfizer.*
</Summary>


<Agent_report>
Query: Analyze Pfizer daily price data since 2000 to compute probability its close price is higher after 9 trading days when current price is in top decile of 52-week range and prior 5-day return is positive; compare against unconditional rate.
The focal question is whether the market-close price of Pfizer Inc. (PFE) tends to be higher nine trading days after today when (a) today’s price sits in the upper-10 % of its trailing 52-week range and (b) the trailing 5-day return is positive.  
Using a daily history that runs from 02 Jan 2000 through 27 Feb 2026 (≈ 6 700 calendar days; 5 000+ NYSE sessions), 2 506 overlapping, non-holiday 9-day return windows were constructed.¹ Each window records:

• day t close,  
• 9-day forward close (t + 9),  
• whether day t close is in the top decile of the rolling 52-week high/low band,  
• whether the backward-looking 5-day close-to-close return ending on day t is positive.

Key unconditional result  
• Across all 2 506 windows, the next-9-trading-day return is positive 52.4 % of the time (mean = +0.24 %, σ = 4.41 %). (Historical base rate block in prompt.)

Single-factor conditional results  
• Price in top decile of 52-week range only → P(up | High-Decile) = 58.3 % (254 cases, +5.8 pp vs. unconditional).  
• 5-day return > 0 only → P(up | Pos 5d) = 53.8 % (1 296 cases, +1.3 pp).  
(Same source block.)

Interpretation so far  
Both signals on a stand-alone basis tilt the odds modestly in favour of a 9-day gain, with the 52-week-range filter being noticeably stronger than the momentum filter.

Missing joint statistic  
The original query, however, requires the joint probability:

 P(up | High-Decile AND Pos 5d)

That number is not present in the extracted summary. To compute it we need:
 • The count of windows that simultaneously satisfy both conditions, and  
 • Within that subset, the count whose 9-day return is positive.

Neither count appears in the available search results, and it cannot be derived from the marginal counts alone without an independence assumption, which is unsafe because price-level and recent-momentum variables are typically correlated.

Why the joint figure matters  
If the two filters are positively associated (likely), the joint subset will be smaller than 254 yet more momentum-loaded than the whole High-Decile set; the conditional win-rate could therefore be higher than 58.3 %—but we cannot say by how much without the raw cross-tabulation.

Data sufficiency assessment  
• Daily price history back to 2000 is confirmed as available from multiple vendors (Barchart “Daily data…back to 01/01/2000”; Wiener Börse export; Yahoo Finance).  
• The summary stats needed for unconditional and single-factor conditions are already computed.  
• The one statistic still required—the joint conditional win-rate—must be calculated directly from the underlying window-level dataset.

Conclusion  
1. Unconditional probability of PFE closing higher nine trading days later: 52.4 %.  
2. With only the “top-decile” filter applied: 58.3 %.  
3. With only the “positive 5-day return” filter applied: 53.8 %.  
4. The probability conditional on both filters simultaneously cannot be stated from the current information; the raw window data (or at minimum a 2 × 2 contingency table) is still needed.

Remaining information gap  
• Joint distribution of the two conditioning variables vs. 9-day outcome.

Without it, we cannot finish the requested comparison (“compute probability … when current price is in top decile and prior 5-day return is positive; compare against unconditional rate”) with full precision.

Source notes  
¹ Computations referenced in “=== STOCK RETURN DISTRIBUTION ===” block of the prompt (Yahoo Finance prices, programme output).  
Additional confirmation of historical data availability: Barchart daily file coverage to 2000 (barchart.com, Price-History page) and Wiener Börse export listing for 2000-26 data (wienerborse.at).</Agent_report>


The information has been sourced from the internet and language models (for agent reports). Exercise healthy skepticism toward unverified claims.

Your analysis should have the following components, referring to the above historical context:
(a) Source analysis: Briefly summarize each information source (either web article or Agent report), evaluate source quality and date.
**Opinions are commonplace in writing. For each source, you must be able to discern factual information from opinions. You are advised to strongly consider only opinions originating from identifiable experts or entities**.
(b) Reference class analysis: Identify a few possible reference classes and evaluate respective suitabilities to the forecasting question. If applicable, choose the most suitable one.
(c) Timeframe analysis: State the prediction timeframe (e.g., how many days/months from now?) and examine historical patterns over similar periods
(d) Justification: Integrate the above factors with other points you found relevant to write a justification for your outside view prediction.

Subsequently, calibrate your outside view prediction, considering:
(a) You aim to predict the true probability of an event occurring, not a hedged or overconfident projection of your beliefs.
(b) Is there a rough figure in the sources you can tether your prediction to?
(c) Small differences in probabilities can be significant: 90% is a 9:1 odds and 99% is a 99:1 odds.
(d) Historically, what is the rate of upsets/unexpected outcomes in the domain of this forecasting question? How should this affect your probability?

Format your answer as below:

Analysis:
{Insert your analysis here, following the above components.}

Outside view calibration:
{Insert your calibration of your outside view prediction here.}

Outside View Prediction:
Provide your outside view prediction as a percentage. Be precise — don't round to multiples of 5%.
